Eupraxia Pharmaceuticals (EPRX) Retained Earnings (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has reported Retained Earnings for 5 consecutive years, with -$182.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings fell 4320.58% year-over-year to -$182.2 million; the TTM figure through Mar 2026 stood at -$182.2 million (down 4320.58% YoY), while the FY2025 annual figure was -$169.6 million, down 3975.9% from the prior year.
• Retained Earnings fell to -$182.2 million in Q1 2026 per EPRX's latest filing, from -$169.6 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$2.7 million in Q4 2023 and bottomed at -$182.2 million in Q1 2026.
• Historically, Retained Earnings has averaged -$99.3 million across 5 years, with a median of -$117.6 million in 2024.
• Annual changes were most pronounced in 2023 — Retained Earnings soared 96.5% — and 2026, when it sank 4320.58%.
• Eupraxia Pharmaceuticals' Retained Earnings stood at -$77.3 million in 2022, then soared by 96.5% to -$2.7 million in 2023, then tumbled by 53.72% to -$4.2 million in 2024, then tumbled by 3975.9% to -$169.6 million in 2025, then retreated by 7.46% to -$182.2 million in 2026.
• Business Quant data shows EPRX's Retained Earnings at -$182.2 million in Q1 2026, -$169.6 million in Q4 2025, and -$152.9 million in Q3 2025.